Rafferty Asset Management, LLC Eq Rx, Inc. Transaction History

Rafferty Asset Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$1.66 - $2.31 $161,292 - $224,448	-97,164 Reduced 15.68%	522,633 $1.16 Million
Q2 2023 Aug 11, 2023	SELL	$1.61 - $1.96 $776,839 - $945,717	-482,509 Reduced 43.77%	619,797 $1.15 Million
Q1 2023 May 11, 2023	SELL	$1.8 - $2.83 $228,661 - $359,506	-127,034 Reduced 10.33%	1,102,306 $2.14 Million
Q4 2022 Feb 13, 2023	BUY	$2.05 - $5.5 $1.32 Million - $3.54 Million	644,201 Added 110.09%	1,229,340 $3.02 Million
Q3 2022 Nov 14, 2022	BUY	$0.94 - $5.99 $351,308 - $2.24 Million	373,732 Added 176.78%	585,139 $2.9 Million
Q2 2022 Aug 12, 2022	BUY	$3.2 - $5.69 $676,502 - $1.2 Million	211,407 New	211,407 $991,000

67.8M

Ticker EQRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 448,140,992
Description
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.